G

Geron Corp
D

GERN

1.25500
USD
-0.02
(-1.57%)
مغلق
حجم التداول
218,649
الربح لكل سهم
-0
العائد الربحي
-
P/E
-6
حجم السوق
799,331,786
أصول ذات صلة
ALNY
ALNY
1.29
(0.39%)
329.01 USD
AMGN
AMGN
-2.01
(-0.65%)
306.66 USD
BMY
BMY
-0.525
(-1.07%)
48.455 USD
C
CLDX
0.110
(0.47%)
23.360 USD
GILD
GILD
3.000
(2.65%)
116.210 USD
INCY
INCY
-0.300
(-0.43%)
70.180 USD
المزيد
الأخبار المقالات

العنوان: Geron Corp

القطاع: Healthcare
الصناعة: Biotechnology
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.